It is run as a commercial business and supplies plasma derived products to the National Health Service in the UK as well as to markets in over 45 countries.
Applications using this early discover were limited due to naturally low concentrations of this anti-haemophilic factor in blood and plasma and volume constraints in the circulatory system.
An agreement was reached between the Government, MRC and the Lister Institute and the Blood Products Laboratory was established with funding from the Ministry of Health.
BPL began cross-charging NHS hospitals for its products and limited competition in the international blood plasma market was permitted.
In 2018, when it was the sole owner, the Chinese group Creat had announced that it planned to integrate BPL's operations with German plasma product manufacturer Biotest.
Three years later, the shareholders decided to sell BPL Holdings to Creat, an investment company based in Beijing that owns part of a plasma fractionator in China.
In turn, to complete the agreement, the family group received the support of its co-investors, Ampersand Capital Partners and a wholly owned subsidiary of Abu Dhabi Investment Authority (ADIA).